Information Provided By:
Fly News Breaks for February 14, 2020
NTLA
Feb 14, 2020 | 06:58 EDT
Wedbush analyst David Nierengarten downgraded Intellia Therapeutics to Neutral from Outperform with a $16 price target.
News For NTLA From the Last 2 Days
There are no results for your query NTLA